HRP20201764T1 - Upotreba inhibitora miostatina i kombinacijske terapije - Google Patents
Upotreba inhibitora miostatina i kombinacijske terapije Download PDFInfo
- Publication number
- HRP20201764T1 HRP20201764T1 HRP20201764TT HRP20201764T HRP20201764T1 HR P20201764 T1 HRP20201764 T1 HR P20201764T1 HR P20201764T T HRP20201764T T HR P20201764TT HR P20201764 T HRP20201764 T HR P20201764T HR P20201764 T1 HRP20201764 T1 HR P20201764T1
- Authority
- HR
- Croatia
- Prior art keywords
- myostatin
- smn
- inhibitor
- myostatin inhibitor
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
Claims (15)
1. Inhibitor miostatina koji je selektivan za miostatin za upotrebu u postupku liječenja spinalne mišićne atrofije (SMA) kod subjekta,
pri čemu se selektivni inhibitor miostatina daje u količini efikasnoj za liječenje SMA,
pri čemu je subjekt: (i) na terapiji korektorom za SMN ili je liječen terapijom sa korektorom SMN tijekom šest mjeseci inhibitora miostatina; i (ii) u fazi rasta i/ili ima potrebu za primanjem dugotrajne terapije, gdje dugotrajna terapija po potrebi uključuje održavanje SMA tijekom života, pri čemu je selektivni inhibitor miostatina:
(a) antitijelo, ili njegov dio za vezivanje antigena, koji vezuje pro- ili latentni miostatin, time inhibirajući aktivaciju miostatina; ili
(b) antitijelo, ili njegov dio za vezivanje antigena, koji vezuje zreli miostatin;
i gdje terapija sa korektorom SMN obuhvaća:
i) modifikator spajanja;
ii) zamjenu SMN gena ili genetsku terapiju;
iii) transkripcijski pojačivač za SMN;
iv) pojačivač translacije SMN proteina; ili,
v) stabilizator SMN proteina.
2. Inhibitor miostatina za upotrebu prema zahtjevu 1, gdje je subjekt pedijatrijski subjekt ili mlada odrasla osoba koja još raste i anabolički je aktivna.
3. Inhibitor miostatina za upotrebu prema zahtjevu 1(a), gdje se antitijelo, ili njegov dio za vezivanje antigena, vezuje za prodomen miostatina.
4. Inhibitor miostatina za upotrebu prema zahtjevu 1(a), gdje se antiijtelo, ili njegov dio za vezivanje antigena, ne vezuje za zreli miostatin koji nije povezan sa pro- ili latentnim miostatinom.
5. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu korektor SMN je antisens RNK ili mala molekula.
6. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu subjekt ima SMA koja ograničava kretanje ili SMA koja ne ograničava kretanje.
7. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu subjekt ima dijagnozu tip I SMA, tip II SMA, ili tip III SMA.
8. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu subjekt ima osnovni rezultat ≤ 65 Proširene Hammersmith-ove Funkcionalne Motorne Skale prije davanja inhibitora miostatina.
9. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu količina efikasna za liječenje SMA je količina koja je efikasna za:
a) odlaganje ili ublažavanje mišićne atrofije;
b) odlaganje gubitka α-motornih neurona;
c) sprječavanje ili odlaganje ekspresije nezrelih mišićnih markera;
d) sprječavanje, ublažavanje ili odlaganje intramuskularnih naslaga masti naznačeno sa masnom zamjenom mišićnog tkiva;
e) povećanje rezultata Proširene Hammersmith-ove Funkcionalne Motorne Skale za ≥ 1 bodova u usporedbi sa netretiranom kontrolnom grupom, ili, za ≥ 1 bodova od osnovnog mjereno prije tretmana;
f) odlaganje napredovanja bolesti prema Proširenoj Hammersmith-ovoj Funkcionalnoj Motornoj Skali tijekom perioda od 12 mjeseci, 24 mjeseca ili 36 mjeseci;
g) povećanje CHOP INTEND rezultata za ≥ 1 bodova u usporedbi sa netretiranom kontrolom; i/ili,
h) povećanje MFM-32 rezultata za najmanje 1 bod u usporedbi sa netretiranom kontrolom.
10. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu je inhibitor namijenjen za davanje preko intravenozne injekcije ili infuzije ili preko subkutanozne injekcije.
11. Inhibitor miostatina za upotrebu prema bilo kojem od prethodnih zahtjeva, gdje je inhibitor antitijelo, ili njegov dio za vezivanje antigena, koji:
(a) sadrži šest područja za određivanje komplementarnosti (CDRs): CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, i CDRL3, gdje:
CDRH1 sadrži sekvencu kao što je predstavljena u SEQ ID NO: 1 ili 2;
CDRH2 sadrži sekvencu kao što je predstavljena u SEQ ID NOs: 4 ili 5;
CDRH3 sadrži sekvencu kao što je predstavljena u SEQ ID NO: 10;
CDRL1 sadrži sekvencu kao što je predstavljena u SEQ ID NOs: 12 ili 13;
CDRL2 sadrži sekvencu kao što je predstavljena u SEQ ID NOs: 18 ili 19; i
CDRL3 sadrži sekvencu kao što je predstavljena u SEQ ID NO: 22;
(b) sadrži varijabilnu regiju teškog lanca koji se sastoji iz aminokiselinske sekvence SEQ ID NO:25 i varijabilnu regiju lakog lanca koji se sastoji iz aminokiselinske sekvence SEQ ID NO:31; ili
(c) sadrži teški lanac koji se sastoji iz aminokiselinske sekvence SEQ ID NO:50 i laki lanac koji se sastoji iz aminokiselinske sekvence SEQ ID NO:51.
12. Inhibitor miostatina koji je selektivan za miostatin, korektor SMN, za upotrebu u postupku liječenja spinalne mišićne atrofije (SMA) kod subjekta, pri čemu je subjekt u fazi rasta i/ili ima potrebu za primanjem dugotrajne terapije, pri čemu dugotrajna terapija po potrebi uključuje održavanje SMA tijekom života, pri čemu je selektivni inhibitor miostatina:
(a) antitijelo, ili njegov dio za vezivanje antigena, koji vezuje pro- ili latentni miostatin, time inhibirajući aktivaciju miostatina; ili
(b) antitijelo, ili njegov dio za vezivanje antigena, koji vezuje zreli miostatin, i gdje korektor SMN sadrži:
i) modifikator spajanja
ii) sredstvo za zamjenu SMN gena ili sredstvo za genetsku terapiju;
iii) pojačivač SMN transkripcije;
iv) pojačivač translacije SMN proteina; ili,
v) stabilizator SMN proteina.
13. Inhibitor miostatina i korektor SMN za upotrebu prema zahtjevu 12, pri čemu inhibitor miostatina i korektor SMN su za konkurentno ili serijsko davanje subjektu.
14. Inhibitor miostatina i korektor SMN za upotrebu prema zahtjevu 12 ili zahtjevu 13, pri čemu subjekt prima korektor SMN i inhibitor miostatina tijekom šest mjeseci jednog od drugog.
15. Inhibitor miostatina i korektor SMN za upotrebu prema bilo kojem od zahtjeva 12-14 gdje je subjekt kao što je definirano u zahtjevu 2 ili 6-8; pri čemu je selektivni inhibitor miostatina kao što je definirano u bilo kojem od zahtjeva 3, 4 ili 11; pri čemu korektor SMN je kao što je definirano u zahtjevu 5; pri čemu je selektivni inhibitor miostatina za davanje u količini koja je efikasna za liječenje SMA kako je definirano u zahtjevu 9; i/ili gdje selektivni inhibitor miostatina je za davanje kao što je definirano u zahtjevu 10.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349596P | 2016-06-13 | 2016-06-13 | |
| US201762470157P | 2017-03-10 | 2017-03-10 | |
| US201762486934P | 2017-04-18 | 2017-04-18 | |
| US201762511702P | 2017-05-26 | 2017-05-26 | |
| US201762512254P | 2017-05-30 | 2017-05-30 | |
| PCT/US2017/037332 WO2017218592A1 (en) | 2016-06-13 | 2017-06-13 | Use of myostatin inhibitors and combination therapies |
| EP17732001.7A EP3368069B1 (en) | 2016-06-13 | 2017-06-13 | Use of myostatin inhibitors and combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201764T1 true HRP20201764T1 (hr) | 2020-12-25 |
Family
ID=59093642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201764TT HRP20201764T1 (hr) | 2016-06-13 | 2017-06-13 | Upotreba inhibitora miostatina i kombinacijske terapije |
| HRP20260160TT HRP20260160T1 (hr) | 2016-06-13 | 2017-06-13 | Uporaba inhibitora miostatina i kombiniranih terapija |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20260160TT HRP20260160T1 (hr) | 2016-06-13 | 2017-06-13 | Uporaba inhibitora miostatina i kombiniranih terapija |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10946036B2 (hr) |
| EP (3) | EP3785728A3 (hr) |
| JP (5) | JP6823167B2 (hr) |
| KR (5) | KR20260028184A (hr) |
| AU (4) | AU2017283546C1 (hr) |
| CL (1) | CL2018003588A1 (hr) |
| CY (1) | CY1123678T1 (hr) |
| DK (2) | DK3368069T3 (hr) |
| ES (1) | ES2830440T3 (hr) |
| FI (1) | FI4218804T3 (hr) |
| HR (2) | HRP20201764T1 (hr) |
| HU (1) | HUE051480T2 (hr) |
| IL (3) | IL301468A (hr) |
| LT (2) | LT3368069T (hr) |
| MY (2) | MY199499A (hr) |
| NZ (3) | NZ789250A (hr) |
| PE (1) | PE20190205A1 (hr) |
| PT (1) | PT3368069T (hr) |
| RS (1) | RS61090B1 (hr) |
| SI (2) | SI4218804T1 (hr) |
| SM (1) | SMT202000598T1 (hr) |
| WO (1) | WO2017218592A1 (hr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| HK1243940A1 (zh) | 2014-11-06 | 2018-07-27 | Scholar Rock, Inc. | 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途 |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| CN114773470A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| LT3350220T (lt) | 2015-09-15 | 2021-09-27 | Scholar Rock, Inc. | Anti pro/latentinio miostatino antikūnai ir jų panaudojimas |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| AU2017283546C1 (en) | 2016-06-13 | 2020-11-19 | Scholar Rock, Inc. | Use of myostatin inhibitors and combination therapies |
| KR102306744B1 (ko) * | 2016-06-17 | 2021-09-28 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체 및 사용 방법 |
| TWI693940B (zh) | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Ｉｌ-８相關疾病之治療用或預防用組成物 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| ES2944357T3 (es) * | 2017-01-06 | 2023-06-20 | Scholar Rock Inc | Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina |
| EP3606562A4 (en) * | 2017-04-03 | 2020-11-11 | Acceleron Pharma Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SPINAL AMYOTROPHIA |
| JP7312749B2 (ja) | 2017-08-04 | 2023-07-21 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングをモジュレートする方法および組成物 |
| WO2019170930A1 (es) * | 2018-03-09 | 2019-09-12 | Universitat De Lleida | Tratamiento para la atrofia muscular espinal |
| JP2021521889A (ja) * | 2018-04-17 | 2021-08-30 | アプライド ステムセル，インコーポレイテッド | 脊髄性筋萎縮症を処置するための組成物および方法 |
| AR117918A1 (es) | 2019-01-30 | 2021-09-01 | Scholar Rock Inc | COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020254342A1 (en) * | 2019-06-19 | 2020-12-24 | F. Hoffmann-La Roche Ag | Digital biomarker |
| CN113993452A (zh) * | 2019-06-19 | 2022-01-28 | 豪夫迈·罗氏有限公司 | 数字生物标志物 |
| US11918570B2 (en) | 2020-04-13 | 2024-03-05 | The Research Foundation For The State University Of New York | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition |
| WO2022093724A1 (en) | 2020-10-26 | 2022-05-05 | Scholar Rock, Inc. | Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy |
| MX2023014840A (es) | 2021-06-23 | 2024-02-12 | Scholar Rock Inc | Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos. |
| EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
| WO2023057404A1 (en) * | 2021-10-06 | 2023-04-13 | F. Hoffmann-La Roche Ag | Novel combined administration |
| DK4518970T3 (da) * | 2022-05-04 | 2026-04-07 | Scholar Rock Inc | Anvendelse af myostatinhæmmer til behandling af spinal muskelatrofi |
| IL321628A (en) | 2022-12-22 | 2025-08-01 | Scholar Rock Inc | Selective and potent inhibitory antibodies for myostatin activation |
| WO2026008041A1 (zh) * | 2024-07-04 | 2026-01-08 | 江苏恒瑞医药股份有限公司 | 特异性结合潜伏肌生长抑制素的抗原结合分子及其医药用途 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2194660C (en) | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| DE60128914T2 (de) | 2001-10-05 | 2008-05-08 | Affimed Therapeutics Ag | Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| US20040044063A1 (en) | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
| US20040219142A1 (en) | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
| EP2192129A1 (en) | 2002-09-16 | 2010-06-02 | Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| DE60333228D1 (de) | 2002-12-02 | 2010-08-12 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
| CA2551877A1 (en) | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| EP1729793B1 (en) | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| AU2005247508A1 (en) | 2004-05-27 | 2005-12-08 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) * | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| NL1031674C2 (nl) | 2005-04-25 | 2007-04-26 | Pfizer | Antilichamen tegen myostatine. |
| ES2534760T3 (es) | 2005-08-19 | 2015-04-28 | Wyeth Llc | Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| WO2008030367A2 (en) * | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| CA2693178C (en) | 2006-11-29 | 2018-12-04 | Nationwide Children's Hospital, Inc. | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| WO2008103471A2 (en) | 2007-02-23 | 2008-08-28 | The Trustees Of Columbia University In The City Of New York | Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease |
| EP2129742B1 (en) | 2007-03-30 | 2012-01-25 | Merck Patent GmbH | Birefingent layer with negative optical dispersion |
| AU2008239606A1 (en) | 2007-04-12 | 2008-10-23 | Paratek Pharmaceuticals, Inc. | Methods for treating spinal muscular atrophy using tetracycline compounds |
| AU2008260445A1 (en) | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| EP2401293B1 (en) | 2009-02-24 | 2016-02-10 | The Salk Institute For Biological Studies | Designer ligands of tgf-beta superfamily |
| JP5766179B2 (ja) | 2009-04-27 | 2015-08-19 | ノバルティス アーゲー | 筋肉増殖を増加させるための組成物および方法 |
| BRPI1010587A2 (pt) | 2009-06-08 | 2019-04-09 | Acceleron Pharma Inc. | métodos para aumentar adipócitos termogênicos |
| EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| US8999343B2 (en) | 2010-08-16 | 2015-04-07 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| CA2852127C (en) | 2011-11-11 | 2020-10-27 | Duke University | Combination drug therapy for the treatment of solid tumors |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| EP2861617A1 (en) | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| US20150284455A1 (en) | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
| MX380973B (es) * | 2013-05-01 | 2025-03-12 | Genzyme Corp | Composiciones y metodos para tratar la atrofia muscular espinal. |
| HRP20251426T1 (hr) | 2013-05-06 | 2026-01-02 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| US10004814B2 (en) | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| HK1243940A1 (zh) | 2014-11-06 | 2018-07-27 | Scholar Rock, Inc. | 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途 |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| WO2016168613A1 (en) * | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| LT3350220T (lt) | 2015-09-15 | 2021-09-27 | Scholar Rock, Inc. | Anti pro/latentinio miostatino antikūnai ir jų panaudojimas |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| AU2017283546C1 (en) | 2016-06-13 | 2020-11-19 | Scholar Rock, Inc. | Use of myostatin inhibitors and combination therapies |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
-
2017
- 2017-06-13 AU AU2017283546A patent/AU2017283546C1/en active Active
- 2017-06-13 IL IL301468A patent/IL301468A/en unknown
- 2017-06-13 PE PE2018003207A patent/PE20190205A1/es unknown
- 2017-06-13 ES ES17732001T patent/ES2830440T3/es active Active
- 2017-06-13 NZ NZ789250A patent/NZ789250A/en unknown
- 2017-06-13 SM SM20200598T patent/SMT202000598T1/it unknown
- 2017-06-13 SI SI201731653T patent/SI4218804T1/sl unknown
- 2017-06-13 IL IL326484A patent/IL326484A/en unknown
- 2017-06-13 SI SI201730485T patent/SI3368069T1/sl unknown
- 2017-06-13 EP EP20179533.3A patent/EP3785728A3/en active Pending
- 2017-06-13 KR KR1020267004587A patent/KR20260028184A/ko active Pending
- 2017-06-13 WO PCT/US2017/037332 patent/WO2017218592A1/en not_active Ceased
- 2017-06-13 KR KR1020237005734A patent/KR20230028813A/ko not_active Ceased
- 2017-06-13 FI FIEP23157280.1T patent/FI4218804T3/fi active
- 2017-06-13 EP EP17732001.7A patent/EP3368069B1/en active Active
- 2017-06-13 DK DK17732001.7T patent/DK3368069T3/da active
- 2017-06-13 HU HUE17732001A patent/HUE051480T2/hu unknown
- 2017-06-13 EP EP23157280.1A patent/EP4218804B1/en active Active
- 2017-06-13 KR KR1020197000822A patent/KR102271635B1/ko active Active
- 2017-06-13 JP JP2019517209A patent/JP6823167B2/ja active Active
- 2017-06-13 LT LTEP17732001.7T patent/LT3368069T/lt unknown
- 2017-06-13 DK DK23157280.1T patent/DK4218804T3/da active
- 2017-06-13 MY MYPI2020004682A patent/MY199499A/en unknown
- 2017-06-13 RS RS20201327A patent/RS61090B1/sr unknown
- 2017-06-13 HR HRP20201764TT patent/HRP20201764T1/hr unknown
- 2017-06-13 KR KR1020217019817A patent/KR20210082548A/ko not_active Ceased
- 2017-06-13 HR HRP20260160TT patent/HRP20260160T1/hr unknown
- 2017-06-13 PT PT177320017T patent/PT3368069T/pt unknown
- 2017-06-13 KR KR1020237042111A patent/KR20230169484A/ko not_active Ceased
- 2017-06-13 NZ NZ789269A patent/NZ789269A/en unknown
- 2017-06-13 LT LTEP23157280.1T patent/LT4218804T/lt unknown
- 2017-06-13 MY MYPI2018002494A patent/MY185614A/en unknown
- 2017-06-13 NZ NZ789268A patent/NZ789268A/en unknown
- 2017-06-13 US US16/308,007 patent/US10946036B2/en active Active
-
2018
- 2018-12-05 IL IL263510A patent/IL263510A/en unknown
- 2018-12-13 CL CL2018003588A patent/CL2018003588A1/es unknown
-
2020
- 2020-07-27 AU AU2020210134A patent/AU2020210134B2/en active Active
- 2020-11-03 CY CY20201101038T patent/CY1123678T1/el unknown
-
2021
- 2021-01-05 JP JP2021000367A patent/JP7161554B2/ja active Active
- 2021-02-03 US US17/248,700 patent/US20210283166A1/en active Pending
- 2021-11-04 AU AU2021261907A patent/AU2021261907B2/en active Active
-
2022
- 2022-04-08 JP JP2022064360A patent/JP7344337B2/ja active Active
-
2023
- 2023-09-01 JP JP2023142275A patent/JP2023164920A/ja active Pending
-
2024
- 2024-05-22 AU AU2024203412A patent/AU2024203412A1/en active Pending
-
2025
- 2025-08-19 JP JP2025136177A patent/JP2025183233A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201764T1 (hr) | Upotreba inhibitora miostatina i kombinacijske terapije | |
| JP2019523295A5 (hr) | ||
| SI2780368T1 (en) | INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A | |
| RU2008137764A (ru) | Способы предотвращения и лечения амилоидных заболеваний | |
| RU2017120437A (ru) | Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r | |
| HRP20231338T1 (hr) | Kombinirana terapija hbv | |
| HRP20212028T1 (hr) | Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 | |
| JP2011506483A5 (hr) | ||
| HRP20230886T1 (hr) | Siguran i učinkovit postupak za liječenje ulcerativnog kolitisa s protutijelom anti-il12/il23 | |
| EA201070740A1 (ru) | Способ лечения перелома кости антителами против склеростина | |
| HRP20241143T1 (hr) | Postupci za liječenje progresivne multiple skleroze primjenom protutijela anti-cd20 | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| CN101370831A (zh) | 用于治疗过敏性疾病的针对胸腺基质淋巴细胞生成素受体的抗体 | |
| IL276896B1 (en) | Methods for treating Crohn's disease with a specific anti-IL23 antibody | |
| US20210009667A1 (en) | Anti-neurotensin long fragment antibodies and uses thereof | |
| JP2018529661A5 (hr) | ||
| JP2021502349A5 (hr) | ||
| JP2020502261A5 (hr) | ||
| JPWO2020059847A5 (hr) | ||
| RU2020133229A (ru) | Антитела к klk5 и способы применения | |
| JP2018535961A5 (hr) | ||
| SI2739311T1 (en) | Method for the treatment of bone defect defects | |
| RU2020133768A (ru) | Способ лечения астмы или аллергического заболевания | |
| US10077303B2 (en) | Anti-neurotensin antibodies and uses thereof | |
| CN115884789A (zh) | Pi4k抑制剂的抗冠状病毒效果以及应用 |